The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
- 22 June 2017
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (10), e400-e403
- https://doi.org/10.3324/haematol.2017.169334
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitorJournal of Hematology & Oncology, 2016
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2016
- Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination TherapyClinical Cancer Research, 2016
- Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophagesHaematologica, 2015
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapyHaematologica, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibNew England Journal of Medicine, 2014
- Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicityBlood, 2014
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximabBlood, 2013
- Differential Regulation of Human NK Cell-Mediated Cytotoxicity by the Tyrosine Kinase ItkThe Journal of Immunology, 2007